Long-term amelioration of an early-onset familial atrial fibrillation model with AAV-mediated in vivo gene therapy.

ABSTRACT: Atrial fibrillation (AF) is a common cardiac disease with high prevalence in the general population. Despite a mild manifestation at the onset stage, it causes serious consequences, including sudden death, when the disease progresses to the late stage. Most available treatments of AF focus on symptom management or alleviation, due to a lack of fundamental knowledge and the fact that considerable variations of AF exist. With the popularisation of the next-generation sequencing technology, several causal genetic factors, including MYL4, have been discovered to contribute to AF, giving hope to developing its gene therapies. In this study, we attempted to treat a previously established rat AF model, which carried Myl4^E11K/E11K loss of function mutation, via overexpression of

SUBMITTER: Hu H 

PROVIDER: S-EPMC11197581 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature